In SSc-ILD patients treated with tocilizumab (anti-IL6Rɑ), CCL18 levels rapidly declined, exhibiting a pharmacodynamic response to IL6 inhibition, and lung function decline was significantly attenuated in tocilizumab-treated as compared to placebo-treated patients despite a lack of significant benefit on skin fibrosis outcomes (76, 77). This evidence concerns the gene IL6 and systemic sclerosis.